Clinical trials: Immunologic Deficiency Syndrome
HIV Infections
Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1
The purpose of this study was to assess the safety, tolerability, antiviral activity, and pharmacokinetics of long-acting cabotegravir (CAB LA) plus the broadly neutralizing monoclonal antibody VRC-HIVMAB075-00-AB (VRC07-523LS)…
- Trial name
- NCT03739996
- Testing
- Oral Cabotegravir (CAB), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Long-Acting Injectable Cabotegravir (CAB LA)
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 75 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hiv, Substance Use Disorders
PrEP at a Syringe Services Program
The purpose of this study is to see if providing participants with pre-exposure prophylaxis (PrEP) medicine right away at the IDEA Exchange will help participants remain in HIV negative.
- Trial name
- NCT04782180
- Testing
- Descovy 200Mg 25Mg Tablet, PrEP
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Miami
Hepatitis C
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A study of the efficacy and safety of the combination of daclatasvir and sofosbuvir in the treatment of hepatitis C virus and HIV coinfection.
- Trial name
- NCT02032888
- Testing
- Daclatasvir, Sofosbuvir
- Where
- 37 sites in United States
- Volunteers
- 238 people
- Sponsor
- Bristol-Myers Squibb
Human Immunodeficiency Virus Type 1 (HIV-1)
A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants
This sub-study will assess the pharmacokinetics (PK), safety, tolerability, virologic efficacy and health outcomes of CAB (GSK1265744) and RPV long acting (LA) in HIV-infected adult participants currently enrolled in the…
- Trial name
- NCT05896761
- Testing
- Cabotegravir Injectable Suspension, Rilpivirine Injectable Suspension
- Where
- 32 sites in United States, Argentina and 5 more
- Volunteers
- 118 people
- Sponsor
- ViiV Healthcare
Human Immunodeficiency Virus, Depression
Targeting HIV Retention and Improved Viral Load Through Engagement ('THRIVE')
Many people with HIV infection are not consistently engaged in outpatient HIV care, and avoidance, stigma and denial contribute to poor engagement in HIV care.
- Conditions
- Human Immunodeficiency Virus, Depression, Anxiety
- Trial name
- NCT04481373
- Testing
- THRIVE, Treatment as Usual
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Baylor College of Medicine
HIV-1 Infection
Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
This primary objective of this study is to evaluate the efficacy of a fixed dose combination (FDC) containing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + a FDC containing…
- Trial name
- NCT02607956
- Testing
- DTG, F/TAF, B/F/TAF
- Where
- 125 sites in United States, Australia and 9 more
- Volunteers
- 657 people
- Sponsor
- Gilead Sciences
HIV Seropositivity, Bisexuality
Telehealth Delivery (Tele-B6)
The research team has developed an interventional group program for young men living with HIV and will be adapting it for telehealth delivery.
- Trial name
- NCT05829759
- Testing
- Tele-B6, Delayed intervention (waitlist control)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Emory University
HIV Enteropathy, Diarrhea With HIV
Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea
This study is being conducted to evaluate the safety and tolerability of crofelemer 125 mg twice a day, taken orally, over 48 weeks of therapy in human immunodeficiency virus-positive (HIV+) subjects with diarrhea.
- Trial name
- NCT01374490
- Testing
- Crofelemer
- Where
- 21 sites in United States
- Volunteers
- 250 people
- Sponsor
- Bausch Health Americas, Inc.
HIV/AIDS
Community Health Worker And MHealth to ImProve Viral Suppression (CHAMPS Pilot)
The overall goal of this study is to evaluate the feasibility of a remotely delivered CHAMPS intervention for people living with HIV (PLWH) in a randomized controlled trial.
- Trial name
- CHAMPS Pilot (NCT05938413)
- Testing
- Wise App with medication adherence reminders, CHW Sessions
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Columbia University
Wiskott-Aldrich Syndrome (WAS)
Gene Therapy for Wiskott-Aldrich Syndrome
This is phase I/II protocol to evaluate the safety and efficacy of WAS gene transfer into hematopoietic stem/progenitor cells for the treatment of Wiskott Aldrich Syndrome.
- Trial name
- TIGET-WAS (NCT01515462)
- Testing
- TLT003
- Where
- Italy
- Volunteers
- 8 people
- Sponsor
- Fondazione Telethon
HIV Infection
ODYSSEY (PENTA 20)
A new anti-HIV medicine (Dolutegravir) combined with 2 currently used anti-HIV medicines is non-inferior to the standard combination of medicines used in terms of efficacy and better in terms of toxicity.
- Trial name
- NCT02259127
- Testing
- Dolutegravir, Standard of Care
- Where
- 28 sites in Germany, Portugal and 6 more
- Volunteers
- 792 people
- Sponsor
- PENTA Foundation
IFN-Gamma Therapy, CGD Gene Mutation
Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease
Background: Chronic granulomatous disease (CGD) is an immunodeficiency disease in which white blood cells are unable to kill certain bacteria and fungi.
- Conditions
- IFN-Gamma Therapy, CGD Gene Mutation, CGD Response to IFNg, CGD - Chronic Granulomatous Disease
- Trial name
- NCT01147042
- Testing
- IFN-gamma
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infection, Human Immunodeficiency Virus, HIV Infections
Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects
This is a 48-week study to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of an investigational regimen including FDA approved HIV drugs in HIV-infected pediatric subjects, ages 4 weeks to < 2 years…
- Trial name
- NCT00071760
- Testing
- GW433908, ritonavir
- Where
- 15 sites in United States, Argentina and 5 more
- Volunteers
- 59 people
- Sponsor
- ViiV Healthcare
HIV Infections
Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid
This study is being done to find out how much of the drug raltegravir (RGV) gets into cerebrospinal fluid (CSF), compared to how much get into the blood and to find out if normal changes in a certain gene in your body affects how…
- Trial name
- NCT00729924
- Testing
- Raltegravir
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Alcohol Dependence, Problem Drinking
Alcohol Pharmacotherapy for HIV+ Prisoners
This is a randomized controlled trial of injectable intramuscular naltrexone (XR-NTX) versus intramuscular placebo among HIV-infected prisoners meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition…
- Conditions
- Alcohol Dependence, Problem Drinking, Hazardous Drinking, Human Immunodeficiency Virus
- Trial name
- INSPIRE (NCT01077310)
- Testing
- Vivitrol- Intramuscular naltrexone (depot-formulation)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Yale University
AIDS, HIV Infections
CSP #512 - Options in Management With Anti-Retrovirals
This 'pragmatic' trial is a 2X2 open randomized study of patients in advanced HIV disease who have failed on conventional Highly Active Antiretroviral Therapy (HAART) regimens including all three classes of anti-HIV drugs.
- Trial name
- OPTIMA (NCT00050089)
- Testing
- No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP, Standard ART vs Mega ART
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 368 people
- Sponsor
- US Department of Veterans Affairs
End Stage Kidney Disease
Phenotyping Seroconversion Following Vaccination Against COVID-19 in Patients on Haemodialysis Study
Patients on haemodialysis are at higher risk of getting a severe form of COVID-19 if they become infected. Vaccinations are soon to arrive and offer great hope of controlling the current pandemic.
- Trial name
- NCT04815850
- Where
- United Kingdom
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- University of Leicester
HIV/AIDS, Medication Adherence
A Text-Based Adherence Game for Young People Living With HIV in Ghana
This study will develop and evaluate a game-based, text message intervention to promote adherence to HIV care among young people living with HIV (YPLH) in Ghana.
- Trial name
- TAG (NCT03928717)
- Testing
- Text-Based Adherence Game, Standard of Care (SOC)
- Where
- Ghana
- Volunteers
- 60 people
- Sponsor
- Rhode Island Hospital
HIV Infections, Memory
Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
Despite the advent of highly active antiretroviral therapy (HAART), the prevalence of neurocognitive impairment among HIV-infected patients continues to be an important issue.
- Trial name
- NCT00893815
- Where
- 3 sites in United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Human Immunodeficiency Virus (HIV), Vitamin D Deficiency
Study of Vitamin D and Effect on Heart Disease and Insulin Resistance
The purpose of this study is to evaluate how Vitamin D affects endothelial function, inflammation, lipids, insulin resistance, vitamin D levels, and parathyroid hormone (PTH).
- Conditions
- Human Immunodeficiency Virus (HIV), Vitamin D Deficiency, HIV Infections
- Trial name
- NCT01093417
- Testing
- Vitamin D
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University Hospitals Cleveland Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.